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Abstract
Pyroptosis is an inflammatory mode of cell death that contributes to the cytokine storm associated
with severe cases of coronavirus disease 2019 (COVID-19). Central to pyroptosis induced by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the formation of the NLRP3 inflammasome.
Inflammasome formation, and by extension pyroptosis, may be inhibited by certain anti-inflammatory
drugs. One such drug, tranilast, is currently being evaluated as a COVID-19 treatment target in a clinical
trial. In this study, we present a single-cell mathematical model that captures the formation of the NLRP3
inflammasome, pyroptotic cell death and drug-responses to tranilast. The model is formulated in terms
of a system of ordinary differential equations (ODEs) that describe the dynamics of proteins involved in
pyroptosis. The model demonstrates that tranilast delays the formation of the NLRP3 inflammasome,
and thus may alter the mode of cell death from inflammatory (pyroptosis) to non-inflammatory (e.g.,
apoptosis).
Key-words
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1 Introduction
SARS-CoV-2 induced pyroptosis and cytokine storms
COVID-19 is a respiratory illness induced by the coronavirus strain SARS-CoV-2 [1]. Most people infected
by the virus experience mild symptoms, however, in cases of severe disease, life-threatening symptoms can
manifest [2]. These divergent disease trajectories have been, largely, attributed to differences in immune
responses of infected hosts [3]. When cells register the presence of SARS-CoV-2 virions, a multitude of
host-protective responses are triggered. Infected cells transmit signals that recruit immune cells, such as
monocytes, macrophages and T-cells, to the site of infection. These immune cells act to eliminate the virus
from the body, and thus they attack infected cells in which virions may replicate. Current research has shown
that, upon active virion replication and release, SARS-CoV-2 can induce pyroptosis in both epithelial cells
and immune cells [3–9]. Pyroptosis is an inflammatory and rapid mode of cell death that is characterised by
the secretion of pro-inflammatory cytokines, cell swelling and, ultimately, membrane rupture resulting in the
release of cytoplasmic contents to the extracellular environment [10,11]. Furthermore, cytokines released by
pyroptosing cells have been shown to induce pyroptosis in neighbouring bystander cells which can register
the cytokines’ damage associated molecular patterns (DAMPs) [12]. Fundamentally, both the recruitment of
immune cells and pyroptotic cell death act to protect the host from the virus. Indeed, in hosts with healthy
immune systems, virus-specific T-cells are recruited to the site of infection [3], and cytokine levels are kept
controlled by negative feedback regulations [13]. However, if the immune system contesting a viral infec-
tion is malfunctioning, a wide array of cytokines may be over-produced due to deregulation of the negative
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feedback that controls cytokine levels in healthy immune systems [13]. Such an over-compensating immune
response may lead to an uncontrolled cytokine activity, commonly referred to as a cytokine storm [3]. Ele-
vated levels of both pro-inflammatory and anti-inflammatory cytokines have been observed in severe cases
of COVID-19 [2, 9, 13, 14], commonly manifesting with severe symptoms such as pneumonia and acute res-
piratory distress syndrome (ARDS), which may lead to multiple organ failure [13]. Hence, cytokine storms
are associated with poor clinical COVID-19 outcomes [2, 4, 6]. Therefore, suppressing the onset of cytokine
storms and the subsequent inflammation, without completely cancelling-out host-protective effects of the
immune system, is one of the suggested treatment strategies explored to combat COVID-19 [13].
One approach to suppress cytokine storms is to inhibit pyroptosis whilst leaving other functionalities of
the immune system untouched. In fact, there exists a number of anti-inflammatory drugs that can inhibit
pyroptosis and, through the inhibition of pyroptosis, alter the cell death mode from inflammatory to non-
inflammatory [15]. Non-inflammatory modes of cell death includes apoptosis, which is characterised by cell
shrinkage with cell membrane integrity maintained throughout cell death, whereas pyroptosis is characterised
by cell swelling and membrane rupture [16,17]. Inhibiting pyroptosis may provide two key clinical advantages.
Firstly, this inhibition can suppress the cytokine storm, and the resulting increased inflammation and tissue
damage that it brings. Secondly, it has been shown that tissue factors released upon pyroptosis may initiate
blood coagulation cascades, therefore inhibiting pyroptosis may reduce the risk of blood clotting in COVID-19
cases [2]. One drug that inhibits pyroptosis is tranilast, an anti-inflammatory drug that is traditionally used
for treating inflammatory diseases, such as asthma, in Japan and South Korea [15]. Tranilast is currently
being re-purposed for treating COVID-19 related symptoms in a clinical trial1 [2, 18].
The pathway to pyroptosis
In this subsection we describe key aspects of the intracellular pathway that leads to pyroptosis. For a
more comprehensive description of the mechanisms driving pyroptosis, we refer the interested reader to
detailed reviews [15, 19–22]. The pathway, as considered in the mathematical model described in Section 2,
is illustrated in Figure 1.
Figure 1. A schematic representation of the pathway to pyroptosis, as considered in our mathematical
model. Black arrows represent reactions that involve mass transfer between depicted compounds. Blue
arrows represent facilitation of compound formation or reactions. Red arrows represent signals that can be
turned on or off in the model. Membrane pores (shown in red) induced by GSDMD-N allows for the
outflux of inflammatory cytokines and the influx of extracellular water, causing the cell to swell and the
cell membrane to eventually rupture. Abbreviations are listed in Appendix A.2.
1Chinese Clinical Trial Registry, registration number: ChiCTR2000030002.
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Central to pyroptosis is the formation of the inflammasome, a multi-protein complex consisting of three
molecular units (a sensor, an adaptor and an executor) that together enable the release of cytokines and the
ultimate membrane rupture that characterise pyroptosis. It has been shown that the NLRP3 inflammasome
can be induced by SARS-CoV-2 [6, 7]. This inflammasome is named after its sensor molecule NLRP3, i.e.
nucleotide-binding and oligomerisation domain (NBD) leucine-rich repeat (LRR)-containing receptors with
an N-terminal pyrin domain (PYD) 3. Thus in this study we focus our attention on the inflammasome
comprising the sensor molecule NLRP3, the adaptor molecule ASC, and the executor molecule caspase-1.
Here, ASC is the apoptosis-associated speck-like protein containing a caspase activation and recruitment
domain (CARD) and a PYD domain, while caspase-1 contains a CARD and a catalytic domain (CD). As
is illustrated in Figure 1, the inflammasome forms via homotypic interactions between NLRP3, ASC and
pro-caspase-1. More specifically, NLRP3-ASC and ASC-caspase-1 bindings are facilitated by PYD-PYD
and CARD-CARD interactions, respectively. Inflammasome formation can be triggered by the presence of
microbial pathogens in a cell, or danger signals from other infected cells. Note that, upon formation, only
one inflammasome is formed per cell [20].
At homeostasis, cells do not contain enough NLRP3 to produce an inflammasome base [21]. Instead, NLRP3
levels are elevated in cells when toll like receptors (TLRs) sense DAMPs or pathogen associated molecular
patterns (PAMPs). As SARS-CoV-2 is a positive sense RNA virus, it can indeed be detected by TLRs [2].
Upon TLRs detecting DAMPs or PAMPs, cytoplasmic nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-κB) is translocated to the nucleus, initiating the transcription and, by extension, the synthesis
of (inactive) NLRP3. The transcription and synthesis of the pro-inflammatory cytokine pro-interleukin-1β
(pro-IL-1β) is also regulated by NF-κB. The transcription-mediated elevation of (inactive) NLRP3 and pro-
IL-1β is often referred to as the priming step of pyroptosis, which is succeeded by the activation step [20].
Inactive NLRP3 can become activated upon stimuli from a wide array intracellular events, including altered
calcium signalling, potassium efflux and the generation of reactive oxygen species (ROS) [15]. In turn, active
NLRP3 molecules can oligomerise and bind together to form a wheel shaped structure, constituting the
inflammasome base. Through homotypic binding, ASC molecules can then bind to the NLRP3 inflamma-
some base. Thereafter, pro-caspase-1 can bind to ASC, enabling the proximity-induced dimerisation, and
thereby the activation, of caspase-1 [23]. Active caspase-1 then acts to cleave the interleukins pro-IL-1β and
pro-interleukin-18 (pro-IL-18) into their respective mature forms, interleukin-1β (IL-1β) and interleukin-18
(IL-18). Caspase-1 also cleaves the protein gasdermin D (GSDMD), releasing the active N-terminal domain
gasdermin D (GSDMD-N) which can form pores on the cell membrane. These pores enable the outflux of
the inflamamtory cytokines IL-1β and IL-18 (in their mature forms) from the cytoplasm to the external
environment [24, 25]. The released cytokines can recruit immune cells to the site of infection and initiate
pyroptosis in neighbouring cells. Note that the GDSMD-N derived membrane pores also allow for the influx
of extracellular material, e.g. water, to the cell. This influx causes cells to swell until their plasma membrane
eventually ruptures, releasing cellular material to the extracellular region. Moreover, data suggests that ASC,
pro-caspase-1, GSDMD and pro-IL-18 are present in adequate levels for NLRP3 formation and pyroptosis
at homeostasis, and thus these proteins are not upregulated by the TLR-stimulated cytoplasm-to-nucleus
translocation of NF-κB [19,26].
Once the NLRP3 inflammasome is activated, cell lysis can be delayed but not prevented [27, 28]. How-
ever, if the formation of the NLRP3 inflammasome is inhibited, a series of intracellular events resulting
in non-inflammatory cell death will instead be initiated. There exists multiple drugs that act to inhibit
inflammasome formation in order to prevent pyroptosis, a rigorous list of covalent drugs that target the
NLRP3 inflammasome can be found in a review by Bertinara et al. [15]. In this study, we include the
pharmacodynamical effects of one of these drugs, namely, tranilast. Tranilast inhibits the formation of the
NLRP3 inflammasome by covalently binding to the NBD domain of NLRP3 molecules, thus preventing
NLRP3-NLRP3 interactions, and the subsequent formation of the NLRP3 inflammasome [29].
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Figure 2. NLRP3 inflammasome formation. (a) Through a wide array of stimuli, inactive NLRP3 can
become activated. These active NLRP3 can then bind together to form the inflammasome base. The
anti-inflammatory drug tranilast inhibits this inflammasome base formation. (b) Once the inflammasome
base is formed, ASC can bind to the NLRP3 molecules in the inflammasome base via homotypic
PYD-PYD interactions. Thereafter, via CARD-CARD interactions, inactive caspase-1 molecules can bind
to NLRP3-bound ASC molecules, and thereby dimerise and activate. Abbreviations used are listed in
Appendix A.2.
Mathematical modelling of pyroptosis
The use of mathematical models to describe apoptotic cell death has been well established and reviewed
[30, 31]. However, there are significantly fewer mathematical models that describe pyroptotic cell death.
Previous modelling works include more implicit descriptions of pyroptosis [32] and descriptions of specific
aspects of inflammasome formation [33–35]. Within this work, we explicitly model the intracellular events
that drive SARS-CoV-2 induced pyroptosis, from TLRs detecting DAMPs/PAMPs through to the ultimate
membrane rupture. We study this system in the absence, or presence, of the anti-inflammatory drug tranilast.
The goal of our model is to capture key aspects of the pyroptosis pathway that are commonly analysed in
experimental studies. Thus, in this mathematical/computational work, we study the time evolution of nuclear
NF-κB, the NLRP3 inflammasome and its components, the pore-forming protein GSDMD, the inflammatory
cytokines IL-1β and IL-18, and cell swelling.
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2 Mathematical model
We formulate a system of ODEs describing the dynamics of the key proteins involved in NLRP3 inflam-
masome formation and pyroptosis. Specifically, the model includes the dynamics of NF-κB (Section 2.1),
NLRP3 (Section 2.2), ASC (Section 2.3), Caspase-1 (Section 2.4), GSDMD (Section 2.5), IL-1β and IL-18
(Section 2.6). We also consider changes in cell volume over time (Section 2.7). In Section 2.8, we expand
the model to include pharmacodynamic effects of the anti-inflammatory drug tranilast. Figure 1 provides
a pictorial overview of the modelled pathway. Variable names are listed in Table 1 in Appendix A.3 and,
throughout this work, the bracket notation [ ] denotes compound concentration. Details concerning mod-
elling steps and parameters can be found in Appendices A.3 and A.4, respectively. Numerical simulation
results are provided in Section 3.
2.1 NF-κB dynamics
When TLRs register DAMPs or PAMPs, cytoplasmic NF-κB is translocated to the nucleus in order to
initiate the transcription of inactive NLRP3 and pro-IL-1β. In the case of SARS-CoV-2, for example, these
DAMPs and PAMPs can be induced by intracellular virion replication and release, or by cytokines from
neighbouring, infected cells. In the model, we consider the cytoplasm-to-nucleus translocation process of
NF-κB to be initiated by a signal S1 that is turned on in response to TLR-sensed signals. The concentrations
of cytoplasmic and nuclear NF-κB are here denoted by [NF-κBc] and [NF-κBn], respectively, and the rate
constants are k1a and k1b. Once the inflammasome base has formed we assume that the translocation of
NF-κB into the nucleus is stopped. Therefore, once F = 0 as defined in Equation (5), the translocation
into the nucleus is prevented, however NF-κB can still return to the cytoplasm. Thus, the rate of change of
[NF-κBc] and [NF-κBn] are described by the equations
[NF-κBc]
dt
= −S1 F k1a [NF-κBc] + k1b [NF-κBn], (1)
[NF-κBn]
dt
= S1 F k1a [NF-κBc]− k1b [NF-κBn], (2)
where we consider the total concentration of NF-κB to be constant over time [36] so that
[NF-κBc] + [NF-κBn] = constant. (3)
The DAMP/PAMP initiated TLR-signal S1 is modelled as a binary on/off function such that
S1 :=
{
1 on, if a DAMP/PAMP induced signal is present,
0 off, otherwise.
(4)
2.2 NLRP3 dynamics
Upon DAMP/PAMP induced TLR-signalling and nuclear NF-κB translocation, inactive NLRP3, NLRP3i, is
transcribed and subsequently synthesised. As the transcription and synthesis of inactive NLRP3 is promoted
by nuclear NF-κB, we describe the production rate of NLRP3 using a Hill function. Specifically, a Hill
function with a constant coefficient rate α1, Hill coefficient γNF and half-max concentration-value NF50
[37]. Inactive NLRP3 can self-activate in response to a secondary signal, S2, which can be turned on by
multiple stimuli such as potassium influx, calcium outflux and abnormal reactive oxygen species (ROS).
Once activated, NLRP3a molecules can oligomerise (bind together) to form a wheel-shaped inflammasome
base, modelled by the concentration of oligomerised NLRP3, i.e., NLRP3o. In the model, we thus consider
NLRP3 protein concentrations in three different forms: [NLRP3i], [NLRP3a] and [NLRP3o]. Inactive and
active NLRP3 decays in the model at a rate δ1. The forward reactions from the inactive-to-active, and active-
to-oligomerised NLRP3 forms are here assumed to be irreversible, and are respectively described using the
rates k2 and k3. We additionally make the assumption that the oligomerisation of active NLRP3 will cease
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once an adequate amount, n, of NLRP3 has oligomerised and formed a base for the inflammasome, thus we
introduce the step-function F , defined as
F = F ([NLRP3o]) :=
{
1 if [NLRP3o] < n,
0 if [NLRP3o] = n.
(5)
We now incorporate all the above mechanisms to describe the rate of change of [NLRP3i], [NLRP3a] and
[NLRP3o] over time as,
d[NLRP3i]
dt
= α1
[NF-κBn]
γNF
NFγNF50 + [NF-κBn]
γNF − S2 k2 [NLRP3i]− δ1 [NLRP3i], (6)
d[NLRP3a]
dt
= S2 k2 [NLRP3i]− k3 F [NLRP3a]− δ1 [NLRP3a], (7)
d[NLRP3o]
dt
= k3 F [NLRP3a], (8)
where the binary signal S2 is set as
S2 :=
{
1 on, if activation signal is present,
0 off, otherwise.
(9)
2.3 ASC dynamics
Once the inflammasome base is formed, that is when F = 1 as defined in Equation (5), free ASC in the cell
can bind to the NLRP3 inflammasome base. Thus in the model, we consider the concentrations of ASC in
free and bound form, denoted [ASCf] and [ASCb], respectively. The inflammasome-forming binding is here
considered to be irreversible and occurs at a rate k4, hence the rate of change of [ASCf] and [ASCb] are here
described by
d[ASCf]
dt
= −k4
(
1− F ) [NLRP3o] [ASCf], (10)
d[ASCb]
dt
= k4
(
1− F ) [NLRP3o] [ASCf]. (11)
Note that, free ASC levels are adequate for pyroptosis at homeostasis [15,19], and thus the total amount of
ASC is constant,
[ASCf] + [ASCb] = constant. (12)
2.4 Caspase-1 dynamics
Pro-caspase-1 can bind to inflammasome-bound ASC upon availability and subsequently dimerise into its
activated, mature form, caspase-1. In the model, concentrations of pro-caspase-1 and caspase-1 are denoted
by [pro-C1] and [C1], respectively. The activation occurs at a rate k5 and is here assumed to be irreversible
so that the rate of change of [pro-C1] and [C1] can be described by
d[pro-C1]
dt
= −k5 [ASCb] [pro-C1], (13)
d[C1]
dt
= k5 [ASCb] [pro-C1]. (14)
Pro-caspase-1 is present in adequate levels in the cell prior to cellular responses to DAMPs or PAMPs [15,19],
therefore the total amount of caspase-1, in both pro- and active form is constant over time so that
[pro-C1] + [C1] = constant. (15)
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2.5 Gasdermin dynamics
GSDMD-N, which is formed as a result of caspase-1 cleavage of GSDMD, produces the pores on the cell
membrane that are central to the pyroptosis process. In the model, we consider the concentrations of both
GSDMD and GSDMD-N, denoted as [GSDMD] and [GSDMD-N], respectively. We describe the caspase-1
facilitated cleavage using a Hill function, where γC1 is the Hill coefficient, and C150 is the half-max [C1]
value. We additionally assume a specific rate for [GSDMD] cleavage, α2. Therefore, we describe the rate of
change of [GSDMD] and [GSDMD-N] in the model, through the equations,
d[GSDMD]
dt
= −α2 [C1]
γC1
C1γC150 + [C1]
γC1 [GSDMD], (16)
d[GSDMD-N]
dt
= α2
[C1]
γC1
C1γC150 + [C1]
γC1 [GSDMD]. (17)
Adequate levels of GSDMD required for pyroptosis are available in the cell at homeostasis [26], therefore we
include a conservation law,
[GSDMD] + [GSDMD-N] = constant. (18)
2.6 Cytokine dynamics
Translocation of NF-κB, from the cytoplasm to the nucleus, induces the transcription and synthesis of pro-
IL-1β. Pro-IL-18, on the other hand, is not synthesised in response to this NF-κB translocation. When active
caspase-1 is available, the pro-forms of the interleukins can be cleaved into their activated forms. Subse-
quently, once membrane pores have been formed in response to GSDMD-N activity, cytoplasmic interleukins
escape to the extracellular region. We here consider the concentrations of IL-1β/18 in pro-, cytoplasmic
and extracellular form, respectively denoted [pro-IL-1β/18], [IL-1βc/18c] and [IL-1βe/18e]. In the model,
pro-IL-1β and pro-IL-18 are cleaved by caspase-1 at rates α4 and α5, respectively. Once cleaved, cellular
IL-1βc and IL-18c escape through the GSDMD-N derived pores at the rates k6 and k7, respectively.
IL-1β: The transcription and synthesis of pro-IL-1β is promoted by [NF-κBn], therefore we describe this
process using a Hill function with constant coefficient α3, Hill coefficient γNF and the half-max concentration
of NF-κB, NF50. We additionally consider the decay of IL-1β at the rate δ2. We incorporate the above
mechanisms to describe the rate of change of [pro-IL-1β], [IL-1βc] and [IL-1βe] over time as,
d[pro-IL-1β]
dt
= α3
[NF-κBn]
γNF
NFγNF50 + [NF-κBn]
γNF − α4
[C1]
γC1
C1γC150 + [C1]
γC1 [pro-IL-1β]− δ2 [pro-IL-1β], (19)
d[IL-1βc]
dt
= α4
[C1]
γC1
C1γC150 + [C1]
γC1 [pro-IL-1β]− k6 G [IL-1βc]− δ2 [IL-1βc], (20)
d[IL-1βe]
dt
= k6 G [IL-1βc]. (21)
Here, G is a function that allows for [GSDMD-N]-dependent cytokine outflux, and water influx, such that,
G = G([GSDMD-N]) :=
[GSDMD-N]
[GSDMD]+[GSDMD-N]
. (22)
IL-18: The above mechanisms are incorporated to describe the rate of change of [pro-IL-18], [IL-18c] and
[IL-18e] over time as,
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d[pro-IL-18]
dt
= −α5 [C1]
γC1
C1γC150 + [C1]
γC1 [pro-IL-18], (23)
d[IL-18c]
dt
= α5
[C1]
γC1
C1γC150 + [C1]
γC1 [pro-IL-18]− k7 G [IL-18c], (24)
d[IL-18e]
dt
= k7 G [IL-18c]. (25)
The levels of pro-IL-18 in the cell are kept at a homeostatic level [15,19], therefore we include a conservation
law,
[pro-IL-18] + [IL-18c] + [IL-18e] = constant. (26)
2.7 Cell volume
The GSDMD-N derived membrane pores that allow for the outflux of mature interleukins, also allow for the
influx of extracellular material (e.g. water). This influx causes the cell to swell until it eventually ruptures.
Single-cell analysis has revealed that before the ultimate membrane rupture occurs, the cell volume increases
gradually [38]. Thus, in the model, we consider the volume of the cell, V , to increase at a rate k8 once pores
are formed on the cell membrane. We describe the rate of change of the cell volume by the equation,
dV
dt
= k8 G V. (27)
Once the cell volume reaches a critical volume Vc then the cell ruptures and all cell processes cease.
2.8 Modified drug targeting model
The anti-inflammatory drug tranilast (TR) binds to the NBD domain of active NLRP3 and thus inhibits the
inflammasome formation by preventing NLRP3-NLRP3 interactions [29]. Thus in the model, we consider
TR binding to NLRP3a to form the complex TR · NLRP3a. The forward and reverse rate constants for this
reaction are denoted by k+TR and k−TR respectively. If we include these drug mechanisms in our model,
Equation (7) describing the dynamics of NLRP3a must be modified to include two additional terms,
d[NLRP3a]
dt
= . . .− k+TR [TR] [NLRP3a] + k−TR [TR · NLRP3a]. (28)
The rate of change of [TR] and [TR · NLRP3a] can now be included in the model as,
d[TR]
dt
= −k+TR [TR] [NLRP3a] + k−TR [TR · NLRP3a], (29)
d[TR · NLRP3a]
dt
= k+TR [TR] [NLRP3a]− k−TR [TR · NLRP3a], (30)
where the following conservation law holds,
[TR]+[TR · NLRP3a] = constant. (31)
2.9 Implementation
The model is implemented in MATLAB [39], where the system of ODEs (1)-(31), given in full in Ap-
pendix A.1, are solved numerically using the function ode15s. A more detailed description of the numerical
set-up can be found in Appendix A.5, which also includes instructions on how to access and run the code.
Simulation results are provided and discussed in the next section.
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3 Results and discussion
We first consider the model without any drug, that is, we simulate the system given by Equations (1)-(27).
Simulation results are provided in Figure 3, in which compound concentrations (in arbitrary units) and cell
volume are plotted over time. These results show that cytoplasmic NF-κB is quickly translocated to the
nucleus upon DAMP/PAMP-induced TLR signalling as [NF-κBc] quickly decreases in favour of [NF-κBn]
at the start of the simulation. Later on, once the inflammasome base has formed, i.e., when [NLRP3o] has
reached the value n, cytoplasmic NF-κB translocates to the nucleus at a decreased rate, thus halting the
transcription, and by extension the synthetisation, of NLRP3i and pro-IL-1β. Synthesised NLRP3i activates
to become NLRP3a, which in turn oligomerises and binds together to form the inflammasome base, here
expressed in terms of the concentration of NLRP3o. These dynamics are captured in the subplot displaying
the time evolution of [NLRP3i], [NLRP3a] and [NLRP3o]. Note that once the inflammasome base is formed,
the NLRP3a-to-NLRP3o oligomerisation stops and the binding of ASC to the inflammasome is initiated.
This can be observed in the results, as [ASCb] levels increase when [NLRP3o] reaches the value n. Further,
as [ASCb] levels increase, the dimerisation and activation of caspase-1 is facilitated so that [pro-C1] levels
decrease and [C1] levels increase. In turn, when [C1] levels increase, the cleavage of GSDMD, pro-IL-1β and
pro-IL-18 occurs. This is apparent in the subplots, as [GSDMD-N], [IL-1βc] and [IL-18c] levels start increas-
ing once [C1] levels surpass zero. The outflux of mature interleukins and the influx of extracellular water to
the cell is mediated by GSDMD-N derived pores, here implicitly modelled via the concentration [GSDMD-N].
Thus, once GSDMD-N has been cleaved, so that [GSDMD-N]>0, the cytoplasmic interleukin concentrations
[IL-1βc] and [IL-18c] respectively decrease in favour of the extracellular concentrations [IL-1βe] and [IL-18e].
[GSDMD-N] levels over zero also enable the cellular volume increase that eventually results in membrane
rupture once the volume reaches the maximal capacity Vc. Note that when membrane rupture occurs, all
intracellular mechanisms are ceased and thus the time progression in the subplots stops.
Figure 3. Numerical simulations results of the ODE model described by Equations (1)-(27) - that is, the
model of pyroptosis in the absence of drugs. We display the concentration of each model component in
arbitrary units (a.u) over time, as well as cell volume dynamics. Note that the time progression stops once
the critical volume Vc is reached and the ultimate cell membrane rupture occurs.
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We next consider numerical simulations of the model including the effects of the drug tranilast, that is
the system given by Equations (1)-(27), with the modifications and additions described in Equations (28)-
(30). The results of the numerical simulations are displayed in Figure 4, where we compare different initial
concentrations (dosages) of the drug. We display the time evolution of each model component in a separate
subplot, where the graph colour corresponds to drug dosage. For all components, increasing levels of the
drug push pyroptotic events further in time. Note that the results for the maximal tested drug dosage
results in many of the processes driving pyroptosis not occurring in the time frame examined. The drug
tranilast specifically inhibits the NLRP3a-to-NLRP3o oligomerisation process. Therefore, when tranilast is
added to the system, we observe that as the drug concentration [TR] increases, so does the amount of time
it takes for [NLRP3o] to reach the threshold value n. This means that the inflammasome base formation,
and by extension the downstream processes resulting in inflammatory cytokine secretion and the ultimate
membrane rupture, are delayed. Recall that if pyroptosis is delayed in a dying cell, the cell death mode can
be altered from inflammatory to non-inflammatory.
Figure 4. Numerical simulations results of the ODE model including the drug tranilast. We display the
concentration of each model component in arbitrary units (a.u) over time, as well as cell volume dynamics
for several dosages of the drug. The dynamics of each model component is plotted in a separate subplot,
where the line colour corresponds to applied drug dosage, as described in the legend. Note that the time
progression stops once the critical volume Vc is reached and the ultimate cell membrane rupture occurs.
4 Conclusions and future work
Pyroptosis has been identified as a key mechanism involved in the cytokine storm and the elevated inflam-
mation associated with severe cases of COVID-19 [2]. Consequently, pyroptosis has been suggested as a
COVID-19 treatment target. In order to investigate the pathway of pyroptosis in further detail, we have in
this study formulated a single-cell mathematical model that captures the key proteins and processes involved
in this pro-inflammatory mode of cell death. Specifically, we model the process from DAMP/PAMP-induced
TLR signalling to cell death and membrane rupture. The model is formulated in terms of a system of ODEs
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describing the dynamics of protein concentrations and cell volume. We further expand the model to include
pharmacodynamic effects of the anti-inflammatory drug tranilast, and our numerical simulations demonstrate
that increasing drug levels result in delayed NLRP3 inflammasome formation, and by extension, delayed cell
rupture. Recently it has been found that if GSDMD-N levels in the cell are low, inflammasome activation
can lead to apoptosis instead of pyroptosis as GSDMD-N inhibits caspase-3 action [11,19,22,40,41]. There-
fore, by delaying the cleavage of GSDMD, the cell death mechanism may be switched from inflammatory
to non-inflammatory. As we have shown in our simulations inclusion of the drug tranilast can delay the
formation of the inflammasome, and therefore may provide a method of switching cell death mode.
In this paper we have provided mathematical model for intracellular pyroptosis dynamics in a non-specified
cell subjected to a non-specified pyroptosis-inducing stimuli. Our model parameter values were motivated
by data from a collection of previous studies with different experimental settings. To quantitatively capture
pyroptosis in a specific setting, we would require access to comprehensive data to update parameter choices
accordingly. Furthermore, comprehensive data would also allow us to evaluate absolute concentrations for
each of the proteins included within the model. With experimentally validated parameter values, a mean-
ingful sensitivity analysis could be performed. However, as described in the Acknowledgements, this work is
part of the Rapid Assistance in Modelling the Pandemic (RAMP) initiative and thus we choose to make our
current work available now.
In regards to further applications of this work, the single cell model developed in this study could be extended
to investigate other anti-inflammatory drugs that target the NLRP3 inflammasome, a comprehensive review
of such drugs is provided by Bertinara et al. [15]. This single cell model could also be incorporated into
multi-cell models in order to study the effect of pyroptosis on a cell population or tissue scale. This would
be especially interesting in a multi-scale model incorporating both epithelial cells and immune cells, as the
release of cytoplasmic cytokines such as IL-1β and IL-18 into the external environment has been linked
to contribute to the cytokine storm. It has been shown that IL-1β can induce pyroptosis in neighbouring
cells [12] and that IL-18 can induce interferon (IFN) γ production in neighbouring cells, which plays a role in
the recruitment of immune cells [42]. Therefore, it would be interesting to study these bystander effects in a
multi-cell setting. Accordingly, we are collaborating with an interdisciplinary coalition of mathematicians and
biologists to model SARS-CoV-2 induced within-host dynamics [43]. This multi-scale model is implemented
in the PhysiCell [44] tissue simulator, allowing for in silico investigations of COVID-19 related dynamics of
epithelial cells, immune cells, virions and cytokines.
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A Appendix
A.1 Complete system of ordinary differential equations
Here, we provide the full system of ODEs, as described in Sections 2.1 through to 2.8. Terms written in
burgundy pertain to drug dynamics and can be excluded from the model if one is interested in simulating
the pyroptosis pathway in the absence of drugs.
[NF-κBc]
dt
= −S1 F k1a [NF-κBc] + k1b [NF-κBn],
[NF-κBn]
dt
= S1 F k1a [NF-κBc]− k1b [NF-κBn],
d[NLRP3i]
dt
= α1
[NF-κBn]
γNF
NFγNF50 + [NF-κBn]
γNF − S2 k2 [NLRP3i]− δ1 [NLRP3i],
d[NLRP3a]
dt
= S2 k2 [NLRP3i]− k3 F [NLRP3a]− δ1 [NLRP3a]−k+TR [TR] [NLRP3a] + k−TR [TR · NLRP3a],
d[NLRP3o]
dt
= k3 F [NLRP3a],
d[ASCf]
dt
= −k4
(
1− F ) [NLRP3o] [ASCf],
d[ASCb]
dt
= k4
(
1− F ) [NLRP3o] [ASCf],
d[pro-C1]
dt
= −k5 [ASCb] [pro-C1],
d[C1]
dt
= k5 [ASCb] [pro-C1],
d[GSDMD]
dt
= −α2 [C1]
γC1
C1γC150 + [C1]
γC1 [GSDMD],
d[GSDMD-N]
dt
= α2
[C1]
γC1
C1γC150 + [C1]
γC1 [GSDMD],
d[pro-IL-1β]
dt
= α3
[NF-κBn]
γNF
NFγNF50 + [NF-κBn]
γNF − α4
[C1]
γC1
C1γC150 + [C1]
γC1 [pro-IL-1β]− δ2 [pro-IL-1β],
d[IL-1βc]
dt
= α4
[C1]
γC1
C1γC150 + [C1]
γC1 [pro-IL-1β]− k6 G [IL-1βc]− δ2 [IL-1βc],
d[IL-1βe]
dt
= k6 G [IL-1βc],
d[pro-IL-18]
dt
= −α5 [C1]
γC1
C1γC150 + [C1]
γC1 [pro-IL-18],
d[IL-18c]
dt
= α5
[C1]
γC1
C1γC150 + [C1]
γC1 [pro-IL-18]− k7 G [IL-18c],
d[IL-18e]
dt
= k7 G [IL-18c],
dV
dt
= k8 G V,
d[TR]
dt
= −k+TR [TR] [NLRP3a] + k−TR [TR · NLRP3a],
d[TR · NLRP3a]
dt
= k+TR [TR] [NLRP3a]− k−TR [TR · NLRP3a].
Where, S1, F , S2 and G are respectively defined in Equations (4), (5), (9) and (22).
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A.2 Abbreviations used in text
• ARDS: acute respiratory distress syndrome
• ASC: apoptosis-associated speck-like protein containing a CARD
• CARD: caspase activation and recruitment domain
• COVID-19: coronavirus disease 2019
• CD: Catalytic domain
• C1-CD: the catalytic domain of caspase-1
• DAMP: damage associated molecular pattern
• GSDMD: gasdermin D
• GSDMD-N: N-terminal domain of GSDMD
• IL-1β: interleukin 1β
• IL-18: interleukin 18
• LLR: leucine-rich repeat
• NBD: nucleotide-binding and oligomerisation domain
• NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells
• NLRP3: NBD, LRR-containing receptors with an N-terminal PYD 3
• ODE: ordinary differential equation
• PAMP: pathogen associated molecular pattern
• pro-IL-1β: pro-form of interleukin 1β
• pro-IL-18: pro-form of interleukin 18
• PYD: pyrin domain
• SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
• TLR: toll like receptor
A.3 Detailed model description and motivation
In this section we provide a detailed model description and justification. Model variables/components are
listed in Table 1 and model parameters are discussed in Appendix A.4.
Signal 1: The initial signal, S1, as defined in equation (4), is here considered to be either on, S1 = 1, or off,
S1 = 0. This binary choice is motivated by the modelling assumption that there will be no inslammasome-
inducing signalling until the DAMP/PAMP-sensing TLR activity is high enough. Therefore any signal level
below some threshold value, here e.g., S1 = 1, would not stimulate a downstream response. We here also
assumed that once S1 is turned on, this signal is kept at a constant level until the cell dies. In future model
adaptations this binary and constant signalling can be modified to allow for continuous responses determined
by internal and external stimuli.
August 11, 2020 16/22
Symbol Component Description
[ASCb](t) concentration of bound ASC protein
[ASCf](t) concentration of free cytosolic ASC protein
[C1](t) concentration of activated caspase-1
[GSDMD](t) concentration of inactive GSDMD
[GSDMD-N](t) concentration of activated GSDMD-N
[IL-1βc](t) concentration of active IL-1β in the cytoplasm
[IL-1βe](t) concentration of active IL-1β external
[IL-18c](t) concentration of active IL-18 in the cytoplasm
[IL− 18e](t) concentration of active IL-18 external
[NF-κBc](t) concentration of cytosolic NF-κB
[NF-κBn](t) concentration of nuclear NF-κB
[NLRP3a](t) concentration of active NLRP3 protein
[NLRP3i](t) concentration of inactive NLRP3 protein
[NLRP3o](t) concentration of oligomerised NLRP3 protein
[pro-C1](t) concentration of pro-caspase-1
[pro-IL-1β](t) concentration of pro-IL-1β
[pro-IL-18](t) concentration of pro-IL-18
S1 first priming signal (e.g., virus)
S2 second activation signal (e.g., ATP)
[TR](t) concentration of free tranilast (drug)
[TR ·NLRP3a](t) concentration of tranilast - NLRPRa complex
V (t) cell volume
Table 1. The symbols and descriptions of the components considered in the model, in alphabetical order.
The bracket notation [ ] denotes compound concentration. Implicit time-dependence is denoted by (t).
NF-κB dynamics: The dynamics of the protein concentrations of cytoplasmic NF-κB, [NF-κBc], and
nuclear NF-κB, [NF-κBn], are described in equations (1) and (2), respectively. When S1 = 1, we assume a
reaction of the form,
NF-κBc
k1a

k1b
NF-κBn. (32)
Applying the law of mass action, we obtain the ODEs for both concentrations [NF-κBc] and [NF-κBn].
NLRP3 dynamics: The dynamics of the concentrations of inactive NLRP3, [NLRP3i], active NLRP3,
[NLRP3a] and oligomerised NLRP3, [NLRP3o] are described in Equations (6), (7) and (8), respectively. To
describe the transcription of inactive NLRP3, which is induced by [NF-κBn] levels, we use a Hill function [37],
[NF-κBn]
γNF
NF γNF50 + [NF-κBn]
γNF
. (33)
Here, NF50 represents the level of [NF-κBn] required for the Hill function to reach the value of a half, often
referred to the half-max value of [NF-κBn] [45]. To incorporate activation of NLRP3 in our model we consider
the reaction,
NLRP3i
k2−→ NLRP3a. (34)
Furthermore, for both inactive and active NLRP3 we include decay reactions of the form,
NLRP3i
δ1−→ ∅, NLRP3a δ1−→ ∅, (35)
where ∅ denotes material outwith the system modelled. Finally, to include oligomerisation of NLRP3, if
F = 1, we consider the reaction
NLRP3a + NLRP3a
k3−→ NLRP3o + NLRP3o. (36)
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For all above reactions, we apply the law of mass action to obtain the ODEs for [NLRP3i], [NLRP3a] and
[NLRP3o]. The NLRP3a-to-NLRP3o oligomerisation step is switched off once [NLRP3o] reaches the level n,
where n corresponds to the concentration required to form an inflammasome base. We include this switch
since only one inflammasome is formed per cell during the pyroptosis process [20]. In the model, this switch is
controlled by the step function F which, as described in Equation (5), is equal to one prior to inflammasome
base formation and zero afterwards.
Signal 2: In the model we assume that the second signal, S2, is either on or off. For all shown simulation
results, we assume that S2 is on, so that S2 = 1, for all time points in the simulation. Through experiments,
Juliana et al. [46] showed that increasing the time that a cell was exposed to ATP (yielding a second signal
S2 to turn on) did not alter the subsequent inflammasome dynamics or the expression of involved proteins.
Thus, it could be argued that assuming that S2 is constant, i.e., on or off, throughout the simulation is a
reasonable model assumption.
ASC dynamics: In the model, we that assume free ASC, ASCf, binds to the inflammasome base, i.e.,
oligomerised [NLRP3o] when F = 0, through a binding reaction,
ASCf + NLRP3o
k4−→ ASCb + NLRP3o. (37)
Again, mass action kinetics allows us to formulate this interaction in terms of ODEs as provided in Equations
(10) and (11).
Caspase-1 dynamics: We assume that pro-caspase-1, pro-C1, binds to inflammasome-bound ASC, ASCb.
This binding is enabled in the model once [ASCb] levels are larger than zero through a the reaction,
ASCb + pro-C1
k5−→ ASCb + C1. (38)
Using mass action kinetics, this reaction can be formulated in terms of the ODEs in Equations (13) and (14).
Gasdermin dynamics: The dynamics of GSDMD and GSDMD-N are described in Equations (16) and
(17). We use a [C1]-dependent Hill function to capture the fact that the cleavage of GSDMD is mediated by
capsase-1. From here, the Hill function inclusive ODE formulation follows the methodology previously de-
scribed for NF-κB-dependent transcription of inactive NLRP3, or in the ODEs, [NF-κB]-dependent elevation
of [NLRP3i].
Cytokine dynamics (IL-1β): The dynamics of IL-1β in the pro-form, pro-IL-1β, the active form in
the cytoplasm, IL-1βc, and the active form released into the external environment, IL-1βe are described in
Equations (19), (20) and (21). We choose a [NF-κB]-dependent Hill function to describe the transcription
of pro-IL-1β, as is done for the transcription of NLRP3. Further, to incorporate the cleavage of pro-IL-1β
by C1, we use a [C1]-dependent Hill function. That is, we assume similar binding-and-cleavage kinetics for
GSDMD and the cytokines. Furthermore, for both concentrations [pro-IL-1β] and [IL-1βc], we include decay
reactions of the form,
pro-IL-1β
δ2−→ ∅, IL-1βc δ2−→ ∅, (39)
where ∅ denotes material outwith the system modelled. Finally, we consider the secretion of cytoplasmic
IL-1β to the external environment to be dependent on the GSDMD-N derived membrane pores. That is, we
assume a [GSDMD-N]-dependent reaction of the form,
IL-1βc
k6−→ IL-1βe. (40)
Again, mass action kinetics allows us to write interactions pertaining to IL-1β dynamics in terms of ODEs,
as provided in Equations (19), (20) and (21).
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Cytokine dynamics (IL-18): The dynamics of IL-18 in the pro-form, pro-IL-18, active form in the
cytoplasm, IL-18c and the active form released to the external environment IL-18c are described in Equations
(23), (24) and (25). Caspase-1 induced cleavage of pro-IL-18 is modelled in the same way as the cleavage
of pro-IL-1β. Moreover, the secretion of cytoplasmic IL-18 to the external environment is modelled as for
IL-1β so that we assume a reaction of the form,
IL-18c
k7−→ IL-18e. (41)
Mass action kinetics allows us to formulate IL-18 related interaction as ODEs, as given in Equations (23),
(24) and (25).
Volume of the cell: The dynamics of the volume of the cell, V , are given in Equation (27). It is assumed
that once pores on the cell membrane form, water can enter the cell and cause the volume of the cell to
increase at the rate k8. Data from single-cell analysis by de Vasconcelos et al. [38] demonstrates pyroptosing
cells increasing 50% in volume prior to the complete membrane rupture. This volume increase was reported
to be gradual (hence here approximated as linear) and started 10-15 minutes before membrane rupture.
Modified drug targeting model: The influence of the drug tranilast is included in a modified version
of the model which results in additional terms for the dynamics of NLRP3a given in Equation (28). Also
included in the drug model is the dynamics of the drug tranilast, TR, and the complex TR · NLRP3a, as is
in Equations (29) and (30). Here, we consider a binding reaction of the form,
TR + NLRP3a
k+TR

k-TR
TR ·NLRP3a. (42)
Mass action kinetics allows us to write this interaction in terms of ODEs. Tranislast is a covalent inhibitor
[15], and thus we could an extra step in the above reaction. However, in lieu of relevant data, we are
currently considering only one reaction step for TR binding to NLRP3o in an effort to not include extra
model parameters.
A.4 Model parameter values
The parameters used to perform numerical simulations of the model are provided in Table 2, unless stated
otherwise. In the following paragraphs we described the reasoning behind the parameter values chosen.
NLRP3 dynamics: In [47], it was found that NLRP3 had a half-life of approximately 6 hrs when stim-
ulated with lipopolysaccharide (LPS), which translates to a decay rate of approximately 0.002 µm min−1.
Therefore we choose,
δ1 = 0.002 min
−1,
as we assume measure concentrations as dimensionless, arbitrary units.
Cytokine dynamics: In [48], it was found that pro-IL-1β had a half-life of approximately 2.5 hrs, which
translates to a decay rate of approximately 0.004 µm min−1. Therefore we choose,
δ2 = 0.004 min
−1,
as we assume measure concentrations as dimensionless, arbitrary units.
The timeline of pyroptosis: We use data from three experimental studies [36,38,49] to further estimate
a timeline for the events regarded in our mathematical model.
Bagaev et al. [36] studied NF-κB kinetics in primary macrophages subjected to bacterial lipopolysaccharide
(LPS). They reported that the nuclear NF-κB concentration peaked at 10 minutes post LPS activation, after
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Symbol Description Value
α1 transcription rate of NLRP3 0.025 (a.u.) min
−1
α2 cleavage rate of GDSMD 0.08 min
−1
α3 transcription rate of pro-IL-1β 0.007 (a.u.) min
−1
α4 cleavage rate of pro-IL-1β 0.8 min
−1
α5 cleavage rate of pro-IL-18 0.8 min
−1
C150 half-max value of caspase-1 required for cleavage 0.3 a.u.
δ1 decay rate of NLRP3 0.002 min
−1
δ2 decay rate of pro-IL-1β and IL-1β 0.004 min
−1
γC1 Hill function coefficient of caspase-1 mediated cleavage 2
γNF Hill function coefficient of NF-κB mediated transcription 2
k1a rate at which NF-κB enters nucleus 0.3 min
−1
k1b rate at which NF-κB leaves nucleus 0.03 min
−1
k2 activation rate of NLRP3 0.07 min
−1
k3 oligomerisation rate of NLRP3 0.07 min
−1
k4 rate for NLRP3 - ASC interaction 0.02 (a.u.)
−1 min−1
k5 rate for ASC - (pro-caspase-1) interactions 0.04 (a.u.)
−1 min−1
k6 transport rate of IL-1β out of cell 0.8 min
−1
k7 transport rate of IL-18 out of cell 0.8 min
−1
k8 rate at which cell volume increases 0.1 min
−1
k+TR forward rate constant for the drug-NLRP3a reaction 0.0035 (a.u.)
−1 min−1
k−TR reverse rate constant for the drug-NLRP3a reaction 0.000035 min−1
n relative level of NLRP3o required for the inflammasome base 1 a.u.
NF50 half-max value of NF-κB required for transcription 0.3 a.u.
Vc critical volume at which cell ruptures 1.5 a.u.
Table 2. Parameters values used within numerical simulations of the model. The justification for these
values is given in Appendix A.4. Here ‘a.u.’ refers to arbitrary units of concentration or volume.
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which it decreased to a half-maximal level in a gradual manner over 100 minutes.
In a single-cell analysis study, de Vasconcelos et al. [38] investigated subcellular key events that define
pyroptosis. In their article, the authors provide a multitude of data pertaining to bone marrow-derived
macrophages (BMDMs) that undergo caspase-1-dependent pyroptosis upon Bacillus anthracis lethal toxin
(LeTx) stimulation. Some data and information from de Vasconcelos et al. [38] is listed below,
• Cell volume was reported to increase gradually for approximately 13 minutes prior to membrane rup-
ture. The cell volume increases by 50% prior to membrane rupture. (See Figure 6a,b in de Vasconcelos
et al. [38]).
• Supernatants from cell cultures were assayed for LDH activity. LDH is a cytosolic protein that is
released by pyroptotic cells, and LDH activity is commonly used as a marker for plasma rupture in
experimental settings. Data showed that near-maximal supernatant LDH values were reached 120 min-
utes post LeTx stimulation (see Figure 9c in de Vasconcelos et al. [38]). From this we approximate the
time between signal 1 turning on in the model, and complete membrane rupture, to be approximately
2 hours.
• The influx of Ca2+ occurs before total membrane permeabilisation in pyroptosis (see Figure 7 in de
Vasconcelos et al. [38]). Further data suggests that changes in mitochondrial activity occur between
(45+12=56) and (21+9=30) minutes prior to complete membrane rupture (see Figure 1 combined with
Figure 3 and Supplementary Figure 3 in de Vasconcelos et al. [38]). If we assume that Ca2+ influx
and changes in mitochondrial activity commence between the priming and activation events, we can
estimate that the NLRP3 inflammasome base is formed somewhere between 56 to 30 minutes prior
to cell rupture. In the model we use the average value (43 minutes) as a time-point for when the
inflammasome starts forming (i.e. when the concentration of NLRP3o reaches the threshold value n).
In [49], Mart´ın-Sa´nchez et al. measure the levels of pro-IL-1β and external IL-1β over time in mouse bone
marrow-derived macrophages (BMDMs) after inflammasome activation. Their results highlighted that the
release of IL-1β coincided with membrane permeability (pores forming), and eventually all of the pro-IL-1β
present at the start of the experiments was cleaved and released from the cell, with approximately 90%
released within 120 minutes.
Using the above data from Bagaev et al. [36], de Vasconcelos et al. [38] and Mart´ın-Sa´nchez et al. [49], we
construct the following timeline for the key events in our model:
• 0 minutes (start time). Signal 1 (S1) turns on.
• 10 minutes (start time + 10 minutes). The nuclear NF-κB concentration peaks. After this time point,
the cytoplasmic-to-nuclear translocation of NF-κB ceases.
• 77 minutes (end time - 43 minutes). Enough NLRP3 has been transcribed, synthesised and activated
to form the inflammasome base.
• 107 minutes (end time - 13 minutes). The GSDMD-N induced pores start forming, allowing the outflux
of IL-1β and IL-18, as well as the influx of extracellular water causing the cell volume to start increasing.
• 120 minutes (end time). The cell membrane completely ruptures. Around 90% of the pro-IL-1β and
pro-IL-18 will have be cleaved and subsequently released.
We choose the values of α1−α5, C150, γC1, γNF, k1a, k1b, k2−k8, NF50 and Vc to obtain dynamics which
follow this timeline. The values are displayed in Table 2.
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Drug (tranilast) dynamics: We are currently considering drug concentrations to be constant during the
simulated time span, effectively describing an in vitro scenario without drug wash out. This could be altered
to include drug dosages varying in time if appropriate. Immunoblot data presented by Huang et al. [29],
pertaining to LPS-primed bone marrow derived macrophages (BMDMs) treated with TR, demonstrate dose-
dependent (25-100µM) drug responses, where the maximal inhibition was reached at at 100 µM of the drug.
With this motivation, we investigate drug dosages in increments of 25 (here arbitrary concentration units)
and adjust the k−TR/k+TR ratio to be “completely effective” at 100 a.u.. At this stage in the model
development, we interpret this “completely effectiveness” as the membrane rupture being delayed so that it
does not occur within 300 simulated minutes. Accordingly, we set k−TR/k+TR = 0.01a.u..
A.5 MATLAB code and set up of numerical simulations
The mathematical model was implemented in MATLAB using the ODE solver ode15s. We solve the system
of equations with the initial conditions (ICs),
[NF-κBc](0) = 0.75, [NF-κBn](0) = 0.25,
[ASCf](0) = [pro-C1](0) = [GSDMD](0) = [pro-IL-18](0) = V (0) = 1,
while all other variables start out with a zero initial condition, to represent a cell in homeostasis. The ini-
tial conditions pertaining to NF-κB are motivated by previous experiments by Bagaev et al. [36], reporting
initial nuclear NF-κB concentrations to be between 10% and 30% (of the total amount of cellular NF-κB),
depending on cell line. For other variables with a non-zero IC, we set the value 1 to be the initial concen-
tration as we are currently working with arbitrary units of concentration/volume and considering relative
compound concentrations using the conservation laws provided throughout the manuscript. When including
drug dynamics in the model, the drug IC is set to the desired drug dosage. The simulation results provided
in Figures 3 and 4 are obtained by running the code with the ICs described above, along with the parameters
given in Table 2 and the signals S1 and S2 turned on.
The MATLAB code includes two events that allows for parameter updates in the simulation. The first
such event captures the formation of the inflammasome, so that when the concentration [NLRP3o] reaches n,
the required concentration for inflammasome formation, the variable F , as defined in Equation (5), switches
from 1 to 0. The second event is terminal and captures the complete membrane rupture of the cell, so that
when the cell volume V reaches a critical volume Vc, the simulation stops.
The MATLAB code, including user instructions, is available on our project GitHub page:
https://github.com/Pyroptosis.
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